Characteristics of HIV-HCV coinfected patients treated with pegylated interferon-α 2a plus ribavirin (n = 267), grouped as a function of HCV genotype and presence or absence of sustained virological response.

<p>Abbreviations: SNP: Single nucleotide polymorphism. RVR: Rapid virologic response. ETR: Virologic response at the end of treatment. SVR: Sustained virologic response.</p

Percentages of HIV/HCV coinfected patients (HCV genotype 1) with rapid (lined) and sustained (black) virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism and HCV-RNA levels.

<p>Percentages of HIV/HCV coinfected patients (HCV genotype 1) with rapid (lined) and sustained (black) virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism and HCV-RNA levels.</p

Characteristics of HIV-infected patients coinfected by HCV genotype 1 treated with pegylated interferon alpha 2a plus ribavirin (n = 187), grouped as a function of the presence or absence of rapid virological response.

<p>Abbreviations: SNP: Single nucleotide polymorphism. RVR: Rapid virologic response. ETR: Virologic response at the end of treatment. SVR: Sustained virologic response.</p

Characteristics of HIV-HCV coinfected patients treated with pegylated interferon alpha 2a plus ribavirin (n = 267), distributed as a function of the presence or absence of significant liver fibrosis (F3 or F4).

<p>Abbreviations: SNP: Single nucleotide polymorphism. RVR: Rapid virologic response. ETR: Virologic response at the end of treatment. SVR: Sustained virologic response.</p

Response to pegylated interferon-α 2a plus ribavirin of 267 HIV/HCV coinfected patients, grouped as a function of HCV genotype.

<p>Data are shown as absolute number (percentage).</p

Percentages of HIV/HCV coinfected patients with sustained virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism, HCV-RNA levels and presence (black) or absence (white) of significant liver fibrosis.

<p>Percentages of HIV/HCV coinfected patients with sustained virological response to pegylated interferon-α 2a plus ribavirin as a function of IL28B polymorphism, HCV-RNA levels and presence (black) or absence (white) of significant liver fibrosis.</p

Multivariate logistic regression analysis for sustained virological response (SVR) including rapid virological response (RVR) (2A) and HCV viral decline of ≥1.5 log IU/mL at week 2 (2B).

<p>Odds Ratios (OR) and 95% Confidence Interval (95% CI) of each variable are shown to the right of the figure.</p

Demographic, virological and clinical characteristics of the on-treatment population.

<p><b>Legend:</b> number of cases (N); standard deviation (SD); Body mass index (BMI); kilograms (kg); meters (m); acquired immunodeficiency syndrome (AIDS); injecting drugs user (IDU); highly active antiretroviral treatment (HAART); human immunodeficiency virus (HIV); hepatitis C virus (HCV); alanine aminotransferase (ALT); low-density lipoprotein (LDL); interleukin 28B (IL28B); cytosine (C); thymine (T).</p><p>*Classified on the basis of Center for Disease Control and Prevention (CDC) recommendations <i>(Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 years and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR 2008; 57 (No RR-10): 1–14)</i>.</p>†<p>HIV viral load was measured by PCR (CobasTaqMan, Roche Diagnostic Systems Inc., Pleasanton, CA, USA), detection limit set at 20 IU/mL.</p>‡<p>Fibrosis stage was determined by liver biopsy according to METAVIR fibrosis score staging or using liver transient elastography (FibroScan, Echosens, Paris).</p>§<p>Available in 148 (90.8%) patients.</p

Comparison of Positive Predictive Value (PPV) for Sustained Virological Response (SVR) of viral decline of ≥ or < than 1.5 log IU/mL at week 2 after start of therapy relative to IL28B genotype (CC <i>versus</i> non-CC) (Figure 1A), liver fibrosis stage (F0–F2 <i>versus</i> F3–F4) (Figure 1B), HCV genotype (1a <i>versus</i> 1b) (Figure 1C), and baseline HCV viral load (≥600,000 IU/mL <i>versus</i> <600,000 IU/mL) (Figure 1D).

<p><i>P</i> value was obtained using Fisher’s exact test or the chi-square test.</p

Positive predictive value of HCV RNA viral decline at week 2 after starting therapy, HCV baseline viral load and IL28B genotype for Sustained Virological Response.

<p><b>Legend:</b> Hepatitis C virus (HCV); international unit per milliliter (IU/mL); Interleukin 28B (IL28B); number of patients (N); Sustained Virological Response (SVR); Positive predictive value (PPV); 95% Confidence Interval (95% CI); Matched condition (+); Unmatched condition (–). The negative condition refers to: HCV decline of <1.5 log IU/mL, baseline viral load ≥600,000 IU/mL, and IL28B Non-CC genotype.</p><p>*Total population included = 148.</p